Document Detail


A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
MedLine Citation:
PMID:  7766740     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis. METHODS: Two hundred and forty-seven patients with erosive oesophagitis were randomly assigned to 8 weeks of treatment with either 30 mg lansoprazole once daily or 150 mg ranitidine twice daily. RESULTS: Two hundred and forty-two patients were included in the analysis. Lansoprazole (30 mg) daily, healed oesophagitis in 92.1% of patients after 8 weeks of treatment. This was significantly superior to 150 mg ranitidine b.d.s. which healed oesophagitis in 69.9% of patients (P < 0.001). Relief of reflux symptoms was superior with lansoprazole to that with ranitidine. Both lansoprazole and ranitidine were well tolerated with no serious drug-related adverse events noted. CONCLUSION: Lansoprazole, 30 mg once daily, is highly effective and safe in the short-term treatment of erosive oesophagitis.
Authors:
M Robinson; B Sahba; D Avner; N Jhala; P A Greski-Rose; D E Jennings
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  9     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-07-03     Completed Date:  1995-07-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  25-31     Citation Subset:  IM    
Affiliation:
Oklahoma Foundation for Digestive Research, University of Oklahoma Health Center, Oklahoma City 73104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Administration, Oral
Alcohol Drinking
Anti-Ulcer Agents / administration & dosage,  adverse effects,  therapeutic use*
Caffeine / administration & dosage
Double-Blind Method
Drug Evaluation
Esophagitis, Peptic / drug therapy*
Female
Gastroscopy
H(+)-K(+)-Exchanging ATPase / antagonists & inhibitors*
Humans
Longitudinal Studies
Male
Omeprazole / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Ranitidine / administration & dosage,  adverse effects,  therapeutic use*
Smoking
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole; 58-08-2/Caffeine; 66357-35-5/Ranitidine; 73590-58-6/Omeprazole; EC 3.6.1.10/H(+)-K(+)-Exchanging ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.
Next Document:  Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicent...